Abstract
Recent advances in the understanding of cancer immunology and T-cell immunoreceptor (TCR) signaling facilitated the development of a new class of anticancer drugs, checkpoint inhibitors (CPI), which have been successfully used for cancer treatment. According to the 2020 Journal of the American Medical Association Network estimate, up to 233,790 US patients with cancer are eligible for CPI. Whereas the CPI blockade of TCR inhibitory signaling pathways can successfully restore or stimulate an antitumor immune response, up to 40% of patients develop immune-related adverse events (irAE) during treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
